Review
Nature Reviews Cancer 9, 415-428 (June 2009) | doi:10.1038/nrc2644
The biology of ovarian cancer: new opportunities for translation
Robert C. Bast, Jr1, Bryan Hennessy1 & Gordon B. Mills1 About the authors
Abstract
Over the past two decades, the 5-year survival for ovarian cancer patients has substantially improved owing to more effective surgery and treatment with empirically optimized combinations of cytotoxic drugs, but the overall cure rate remains approximately 30%. Many investigators think that further empirical trials using combinations of conventional agents are likely to produce only modest incremental improvements in outcome. Given the heterogeneity of this disease, increases in long-term survival might be achieved by translating recent insights at the molecular and cellular levels to personalize individual strategies for treatment and to optimize early detection.
- View At a Glance
Author affiliations
- Departments of Experimental Therapeutics and Systems Biology, University of Texas M. D. Anderson Cancer Center, 1515 Holcolmbe Boulevard, Houston, Texas 77030, USA.
Correspondence to: Robert C. Bast, Jr1 Email: rbast@mdanderson.org
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cystsBritish Journal of Cancer Original Article
Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancerNature Medicine Article (01 Jan 2005)
Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tractNature Medicine Article (01 Jun 2005)
See all 8 matches for Research